PONAXEN PONATINIB HYDROCHLORIDE 15MG, 45MG

Strengths available :  15mg, 45mg 

Form : Tablets

Dosage : The recommended starting dose is 45mg of Ponaxen once daily. Treatment should be continued as long as the patient does not show evidence of disease progression or unacceptable toxicity. Discontinuing Ponaxen should be considered if a complete haematologic response has not occurred by 3 months (90 days). The risk of arterial  occlusive events is likely to be dose-related. Reducing the dose of Ponaxen to 15mg should be considered for CP-CML patients who have achieved a major cytogenetic response taking the following factors into account in the individual patient assessment cardiovascular risk, side effects of Ponaxen therapy, time to cytogenetic response and BCR-ABL transcript levels. If dose reduction is undertaken, close monitoring of response is recommended. 

Storage : Do not store above 30° C

The common side effects are pneumonia, abdominal pain, pancreatitis, atrial fibrillation, pyrexia, anaemia, myocardial infraction, peripheral arterial occlusive disease, angina pectoris, platelet count decreased, platelet count decreased, hypertension, febrile neutropenia, coronary artery disease, cardiac failure congestive, acute kidney injury, urinary tract infection, lipase increased, cerebrovascular accident, cellulitis and sepsis.